Patents by Inventor Boro Dropulic

Boro Dropulic has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR TREATING CANCER WITH ANTI-BCMA IMMUNOTHERAPY
    Publication number: 20200289572
    Abstract: Chimeric antigen receptors containing BCMA antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
    Type: Application
    Filed: May 29, 2020
    Publication date: September 17, 2020
    Inventors: Dina Schneider, Zhongyu Zhu, Boro Dropulic, Bang Khoa Vu, Leah Marie Alabanza
  • Compositions and Methods for Treating Cancer with Anti-Mesothelin Immunotherapy
    Publication number: 20200231663
    Abstract: Chimeric antigen receptors containing mesothelin antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
    Type: Application
    Filed: February 3, 2020
    Publication date: July 23, 2020
    Inventors: Rimas Orentas, Dina Schneider, Boro Dropulic, Dimiter S. Dimitrov, Zhongyu Zhu
  • Compositions and Methods for Treating Cancer with DuoCARs
    Publication number: 20200231648
    Abstract: Novel therapeutic immunotherapy compositions comprising at least two vectors, each vector encoding a functional CAR, whereby the combination of vectors results in the expression of two or more non-identical binding domains, wherein each vector encoded binding domain(s) are covalently linked to a transmembrane domain and one or more non-identical intracellular signaling motifs are provided herein as well as are methods of use of same in a patient-specific immunotherapy that can be used to treat cancers and other diseases and conditions.
    Type: Application
    Filed: November 22, 2019
    Publication date: July 23, 2020
    Inventors: Rimas J. Orentas, Dina Schneider, Waleed M. Haso, Stefan Miltenyi, Boro Dropulic
  • Compositions and Methods for Treating Cancer with Anti-CD38 Immunotherapy
    Publication number: 20200197440
    Abstract: Chimeric antigen receptors containing CD38 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
    Type: Application
    Filed: November 27, 2019
    Publication date: June 25, 2020
    Inventors: Dina Schneider, Rimas J. Orentas, Boro Dropulic, Dimiter S. Dimitrov, Zhongyu Zhu
  • Compositions and methods for treating cancer with DuoCARs
    Patent number: 10689431
    Abstract: Novel therapeutic immunotherapy compositions comprising at least two vectors, each vector encoding a functional CAR, whereby the combination of vectors results in the expression of two or more non-identical binding domains, wherein each vector encoded binding domain(s) are covalently linked to a transmembrane domain and one or more non-identical intracellular signaling motifs are provided herein as well as are methods of use of same in a patient-specific immunotherapy that can be used to treat cancers and other diseases and conditions.
    Type: Grant
    Filed: September 18, 2018
    Date of Patent: June 23, 2020
    Assignee: LENTIGEN TECHNOLOGY, INC.
    Inventors: Rimas J. Orentas, Dina Schneider, Waleed M. Haso, Stefan Miltenyi, Boro Dropulic
  • Compositions and Methods For Treating Cancer With Anti-CD22 Immunotherapy
    Publication number: 20200155661
    Abstract: Chimeric antigen receptors (CARs) containing CD22 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the CARs are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making CAR T cells are also disclosed.
    Type: Application
    Filed: January 27, 2020
    Publication date: May 21, 2020
    Inventors: Rimas J. Orentas, Dina Schneider, Boro Dropulic, Dimiter S. Dimitrov, Zhongyu Zhu
  • Method to treat cancer with engineered T-cells
    Patent number: 10639329
    Abstract: Novel adoptive immunotherapy compositions comprising co-cultured lentiviral vector-transduced autologous antigen presentation cells and T cells are provided herein as well as are methods of use of same in a patient-specific combination immunotherapy that can be used to treat cancers and other diseases and conditions.
    Type: Grant
    Filed: June 12, 2016
    Date of Patent: May 5, 2020
    Assignee: LENTIGEN TECHNOLOGY, INC.
    Inventors: Boro Dropulic, Rimas Orentas, Dina Schneider, Winfried Krueger
  • Compositions and Methods for Treating Cancer with Anti-CD19 Immunotherapy
    Publication number: 20200123254
    Abstract: Chimeric antigen receptors containing human CD19 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
    Type: Application
    Filed: December 9, 2019
    Publication date: April 23, 2020
    Inventors: Dina Schneider, Rimas J. Orentas, Boro Dropulic, Dimiter S. Dimitrov, Zhongyu Zhu
  • COMPOSITIONS AND METHODS FOR TREATING CANCER WITH ANTI-CD19/CD20 IMMUNOTHERAPY
    Publication number: 20200109210
    Abstract: Chimeric antigen receptors containing CD19/CD20 or CD20/CD19 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
    Type: Application
    Filed: October 11, 2019
    Publication date: April 9, 2020
    Inventors: Rimas J. Orentas, Boro Dropulic, Dina Schneider
  • Compositions and Methods for Treating Cancer with Anti-CD33 Immunotherapy
    Publication number: 20200101109
    Abstract: Chimeric antigen receptors containing CD33 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
    Type: Application
    Filed: September 30, 2019
    Publication date: April 2, 2020
    Inventors: Rimas Orentas, Dina Schneider, Boro Dropulic, Dimiter S. Dimitrov, Zhongyu Zhu
  • Compositions and Methods for Treating Cancer with Anti-ROR1 Immunotherapy
    Publication number: 20200102385
    Abstract: Chimeric antigen receptors containing ROR1 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
    Type: Application
    Filed: September 30, 2019
    Publication date: April 2, 2020
    Inventors: Rimas J. Orentas, Dina Schneider, Boro Dropulic, Dimiter S. Dimitrov, Zhongyu Zhu
  • Compositions and Methods for Treating Cancer with Anti-CD19/CD22 Immunotherapy
    Publication number: 20200087396
    Abstract: Chimeric antigen receptors containing CD19/CD22 or CD22/CD19 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
    Type: Application
    Filed: September 26, 2019
    Publication date: March 19, 2020
    Inventors: Dina Schneider, Rimas J. Orentas, Boro Dropulic, Peirong Hu
  • Chimeric Antigen Receptors and Methods of Use
    Publication number: 20200079849
    Abstract: Chimeric antigen receptors containing tumor necrosis factor receptor superfamily member transmembrane domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
    Type: Application
    Filed: September 23, 2019
    Publication date: March 12, 2020
    Inventors: Rimas Orentas, Dina Schneider, Boro Dropulic
  • Compositions and methods for treating cancer with anti-mesothelin immunotherapy
    Patent number: 10550179
    Abstract: Chimeric antigen receptors containing mesothelin antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: February 4, 2020
    Assignees: Lentigen Technology Inc., The U.S.A., as represented by the Secretary, Department of Health and Human Services
    Inventors: Rimas J. Orentas, Dina Schneider, Boro Dropulic, Dimiter S. Dimitrov, Zhongyu Zhu
  • Compositions and methods for treating cancer with anti-CD22 immunotherapy
    Patent number: 10543263
    Abstract: Chimeric antigen receptors (CARs) containing CD22 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the CARs are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making CAR T cells are also disclosed.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: January 28, 2020
    Assignees: Lentigen Technology Inc., The U.S.A., as represented by the Secretary, Department of Health and Human Services
    Inventors: Rimas J. Orentas, Dina Schneider, Boro Dropulic, Dimiter S. Dimitrov, Zhongyu Zhu
  • Compositions and Methods for Treating Cancer with Anti-CD123 Immunotherapy
    Publication number: 20200010555
    Abstract: Chimeric antigen receptors containing CD123 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
    Type: Application
    Filed: September 20, 2019
    Publication date: January 9, 2020
    Inventors: Rimas J. Orentas, Dina Schneider, Boro Dropulic, Dimiter S. Dimitrov, Zhongyu Zhu
  • Compositions and methods for treating cancer with anti-CD19 immunotherapy
    Patent number: 10501539
    Abstract: Chimeric antigen receptors containing human CD19 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
    Type: Grant
    Filed: September 14, 2018
    Date of Patent: December 10, 2019
    Assignees: Lentigen Technology Inc., The U.S.A., as Represented By The Secretary, Department of Health and Human Services
    Inventors: Dina Schneider, Rimas J. Orentas, Boro Dropulic, Dimiter S. Dimitrov, Zhongyu Zhu
  • Compositions and methods for treating cancer with anti-CD19/CD20 immunotherapy
    Patent number: 10442867
    Abstract: Chimeric antigen receptors containing CD19/CD20 or CD20/CD19 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
    Type: Grant
    Filed: July 31, 2018
    Date of Patent: October 15, 2019
    Assignee: LENTIGEN TECHNOLOGY, INC.
    Inventors: Rimas J. Orentas, Boro Dropulic, Dina Schneider
  • Compositions and methods for treating cancer with anti-CD33 immunotherapy
    Patent number: 10426797
    Abstract: Chimeric antigen receptors containing CD33 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: October 1, 2019
    Assignees: LENTIGEN TECHNOLOGY, INC., United States of America as Represented by the Secretary, The Dept. of Health and Human Services
    Inventors: Rimas Orentas, Dina Schneider, Boro Dropulic, Dimiter S. Dimitrov, Zhongyu Zhu
  • Compositions and methods for treating cancer with anti-ROR1 immunotherapy
    Patent number: 10428141
    Abstract: Chimeric antigen receptors containing ROR1 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: October 1, 2019
    Assignees: LENTIGEN TECHNOLOGY, INC., The U.S.A., as represented by the Secretary, Department of Health and Human Services
    Inventors: Rimas J. Orentas, Dina Schneider, Boro Dropulic, Dimiter S. Dimitrov, Zhongyu Zhu